256 related articles for article (PubMed ID: 34758834)
1. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m
Gao F; Lin MS; You JS; Zhang MY; Cheng L; Lin K; Zhao P; Chen QY
Cancer Cell Int; 2021 Nov; 21(1):601. PubMed ID: 34758834
[TBL] [Abstract][Full Text] [Related]
2. Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.
Byun JM; Lee J; Shin SJ; Kang M; Yoon SS; Koh Y
Blood Res; 2018 Jun; 53(2):105-109. PubMed ID: 29963515
[TBL] [Abstract][Full Text] [Related]
3. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
[TBL] [Abstract][Full Text] [Related]
4. Busulfan plus melphalan
Park S; Shin DY; Hong J; Kim I; Koh Y; Byun JM; Yoon SS
Ther Adv Hematol; 2021; 12():20406207211012985. PubMed ID: 33995990
[TBL] [Abstract][Full Text] [Related]
5. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
[TBL] [Abstract][Full Text] [Related]
7. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
Lahuerta JJ; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez AM; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz JC; Moraleda JM; León A; Bargay J; Cabrera R; Hernandez-García MT; Diaz-Mediavilla J; Miguel JS
Br J Haematol; 2000 Apr; 109(1):138-47. PubMed ID: 10848793
[TBL] [Abstract][Full Text] [Related]
8. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
Bashir Q; Thall PF; Milton DR; Fox PS; Kawedia JD; Kebriaei P; Shah N; Patel K; Andersson BS; Nieto YL; Valdez BC; Parmar S; Rondon G; Delgado R; Hosing C; Popat UR; Oran B; Ciurea SO; Lin P; Weber DM; Thomas SK; Lee HC; Manasanch EE; Orlowski RZ; Williams LA; Champlin RE; Qazilbash MH
Lancet Haematol; 2019 May; 6(5):e266-e275. PubMed ID: 30910541
[TBL] [Abstract][Full Text] [Related]
9. Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment.
Zhou S; Zhai Y; Yan L; Shi X; Shang J; Wu D; Fu C; Jin S
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834886
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
Lahuerta JJ; Grande C; Blade J; Martínez-López J; de la Serna J; Alegre A; Garcia LJ; Caballero D; de la Rubia J; Marín J; Perez-Lopez C; Sureda A; Escudero A; Cabrera R; Conde E; García-Ruiz JC; Pérez-Equiza K; Hernandez F; Palomera L; León A; Giraldo P; Solano C; Bargay J; San MJ;
Leuk Lymphoma; 2002 Jan; 43(1):67-74. PubMed ID: 11908738
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Czerw T; Pabst T; Blaise D; Dumas PY; Nemet D; Arcese W; Trisolini SM; Wu D; Huynh A; Zuckerman T; Meijer E; Cagirgan S; Cornelissen J; Houhou M; Polge E; Mohty M; Nagler A
Cancer; 2017 Mar; 123(5):824-831. PubMed ID: 27906458
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT.
Gorin NC; Labopin M; Blaise D; Dumas PY; Pabst T; Trisolini SM; Arcese W; Houhou M; Mohty M; Nagler A
Am J Hematol; 2018 Jul; 93(7):859-866. PubMed ID: 29644709
[TBL] [Abstract][Full Text] [Related]
13. Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Sanz J; Labopin M; Pabst T; Versluis J; Van Gorkom G; Meijer E; Gedde-Dahl T; Montoro J; Arcese W; Pérez-Simón JA; Schaap N; Maertens J; Vrhovac R; Lanza F; Gorin NC; Mohty M; Ciceri F
Bone Marrow Transplant; 2023 Nov; 58(11):1197-1202. PubMed ID: 37553468
[TBL] [Abstract][Full Text] [Related]
14. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma.
Bommier C; Talbot A; Harel S; Cuccuini W; Gérard L; Arnulf B
Hematol Oncol; 2020 Oct; 38(4):517-522. PubMed ID: 32569436
[TBL] [Abstract][Full Text] [Related]
15. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
16. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.
Hagen P; Norton J; Tsai S; Campo L; Lee M; Gomez K; Stiff P
Br J Haematol; 2024 Apr; 204(4):1422-1428. PubMed ID: 38176404
[TBL] [Abstract][Full Text] [Related]
17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
18. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
Lahuerta JJ; Mateos MV; Martínez-López J; Grande C; de la Rubia J; Rosiñol L; Sureda A; García-Laraña J; Díaz-Mediavilla J; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Oriol A; Escoda L; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF;
Haematologica; 2010 Nov; 95(11):1913-20. PubMed ID: 20663944
[TBL] [Abstract][Full Text] [Related]
19. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
20. Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study).
Song GY; Jung SH; Kim JS; Eom HS; Moon JH; Yhim HY; Kim K; Min CK; Lee JJ
Front Oncol; 2022; 12():959949. PubMed ID: 36110935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]